M
Masafumi Fukagawa
Researcher at Tokai University
Publications - 564
Citations - 16079
Masafumi Fukagawa is an academic researcher from Tokai University. The author has contributed to research in topics: Secondary hyperparathyroidism & Parathyroid hormone. The author has an hindex of 60, co-authored 534 publications receiving 13875 citations. Previous affiliations of Masafumi Fukagawa include University of Copenhagen & Niigata University.
Papers
More filters
Journal ArticleDOI
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
Markus Ketteler,Geoffrey A. Block,Pieter Evenepoel,Masafumi Fukagawa,Charles A. Herzog,Linda M. McCann,Sharon M. Moe,Sharon M. Moe,Rukshana Shroff,Marcello Tonelli,Nigel D Toussaint,Marc G. Vervloet,Mary B. Leonard +12 more
TL;DR: The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKDMBD Guideline published in 2009.
Journal ArticleDOI
Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.
TL;DR: The findings indicate that the conflicting results of biochemical studies may be caused by the heterogeneous distribution of VDR; the decreased VDR density in parathyroids may contribute to the progression of secondary hyperparathyroidism and to the proliferation of parathyroid cells that is seen in uremia.
Journal ArticleDOI
Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency.
Takashi Shigematsu,Junichiro James Kazama,Takeyoshi Yamashita,Seiji Fukumoto,Tatsuo Hosoya,Fumitake Gejyo,Masafumi Fukagawa +6 more
TL;DR: FGF-23 becomes a potential uremic toxin to decrease 1,25D levels when it loses its hypophosphatemic action because of a decreased number of viable nephrons in patients with advanced renal failure and may be an important determinant in the regulation of mineral metabolism with renal insufficiency.
Journal ArticleDOI
Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder
Masafumi Fukagawa,Keitaro Yokoyama,Fumihiko Koiwa,Masatomo Taniguchi,Tetsuo Shoji,Junichiro James Kazama,Hirotaka Komaba,Ryoichi Ando,Takatoshi Kakuta,Hideki Fujii,Msasaaki Nakayama,Yugo Shibagaki,Seiji Fukumoto,Naohiko Fujii,Motoshi Hattori,Akira Ashida,Kunitoshi Iseki,Takashi Shigematsu,Yusuke Tsukamoto,Yoshiharu Tsubakihara,Tadashi Tomo,Hideki Hirakata,Tadao Akizawa +22 more
TL;DR: CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy, and Tadao Akizawa thank the authors for their help and assistance in the development of this guideline.
Journal ArticleDOI
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase
Hiroshi Watanabe,Yohei Miyamoto,Daisuke Honda,Hisae Tanaka,Qiong Wu,Masayuki Endo,Tsuyoshi Noguchi,Daisuke Kadowaki,Yu Ishima,Shunsuke Kotani,Makoto Nakajima,Keiichiro Kataoka,Shokei Kim-Mitsuyama,Motoko Tanaka,Masafumi Fukagawa,Masaki Otagiri,Toru Maruyama +16 more
TL;DR: The renal toxicity of PCS is attributed to its intracellular accumulation, leading to both increased NADPH oxidase activity and ROS production, which, in turn, triggers induction of inflammatory cytokines involved in renal fibrosis.